Akebia Therapeutics Announces New Chief Financial Officer
Spellman will join Akebia from
"We're thrilled to welcome Dave to Akebia and believe he will make an immediate impact at this dynamic time in our history," said
"I can't imagine a more exciting time to join Akebia," said Spellman. "Akebia's unwavering commitment to innovation and advancing patient care is inspiring, and I'm thrilled to become part of it. I look forward to building upon Akebia's financial performance and leading the finance organization for continued success."
Spellman will succeed
"On behalf of the Board and everyone at Akebia, I want to thank Jason for his contributions over the past 7 years. Jason has been a great leader and colleague who has helped create tremendous value for our Company," said Butler. "Thanks to Jason, we have both a strong finance organization and healthy balance sheet that well position us for the future."
Spellman has more than 20 years of strategic and operational finance experience in fast growing companies within the biopharmaceutical and healthcare industries. Prior to joining Intarcia, Spellman served as the Chief Financial Officer of Mersana Therapeutics, Inc., a clinical stage antibody drug conjugate company. From
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor currently in global Phase 3 development for the treatment of anemia due to CKD. Vadadustat is designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat is an investigational therapy and is not approved by the
Statements in this press release regarding Akebia's strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the
View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-announces-new-chief-financial-officer-301079831.html